Case reportSuccessful treatment of cardiac involvement in dermatomyositis with rituximab
References (17)
- et al.
Cardiac troponin and beta-type myosin heavy chain concentrations in patients with polymyositis or dermatomyositis
Clin Chim Acta
(2001) Laboratory testing in the diagnosis and management of idiopathic inflammatory myopathies
Rheum Dis Clin North Am
(2002)- et al.
Adult onset polymyositis/dermatomyositis: an analysis of clinical and laboratory features and survival in 76 patients with a review of the literature
Semin Arthritis Rheum
(1986) - et al.
Inflammatory muscle disease: clinical features
Inflammatory diseases of muscle and other myopathies
Cardiac involvement in autoimmune myositis and mixed connective tissue disease
Lupus
(2005)- et al.
Effects of corticosteroids and immunosuppressors on idiopathic inflammatory myopathy related myocarditis evaluated by magnetic resonance imaging
Ann Rheum Dis
(2006) - et al.
Serum skeletal troponin I in inflammatory muscle disease: relation to creatine kinase, CKMB and cardiac troponin I
Ann Rheum Dis
(2000)
Cited by (50)
Response to cyclophosphamide and rituximab therapy in idiopathic inflammatory myopathies: A single center experience
2021, Egyptian RheumatologistCitation Excerpt :B lymphocytes play an important role in the pathogenesis of IIM, proved by the identification of circulating autoantibodies in 80% of patients, and by B cells demonstration in inflammatory muscle fibers in DM and PM patients, and in perivascular regions of muscles in DM [9,12]. A number of case reports, case series, and very few large treatment trials recommended RTX to be efficient in refractory IIM treatment [5,13–19]. However, no standardized therapeutic guidelines for treatment of IIM have been established, perhaps due to the insufficient randomized controlled trials and the rarity of such diseases.
Dermatomyositis and Polymyositis
2017, The Heart in Rheumatic, Autoimmune and Inflammatory Diseases: Pathophysiology, Clinical Aspects and Therapeutic ApproachesThe skin in autoimmune diseases—Unmet needs
2016, Autoimmunity ReviewsCitation Excerpt :Data on the treatment of skin involvement in patients with DM applying biological agents, however, are only available from open-label studies, retrospective reviews, case series, and a few randomized controlled trials. Rituximab was applied in patients with DM in case series and open-label trials [90], and an improvement of cutaneous involvement was reported in a few cases [108,109]. Only one trial, however, applied a validated skin activity score (the Dermatomyositis Skin Severity Index, DSSI) as a primary outcome [110]; compared to the baseline value, the mean DSSI was improved after 24 weeks of treatment with rituximab, but the difference was not significant.
Myocarditis in connective tissue diseases: an often-overlooked clinical manifestation
2023, Rheumatology InternationalThe potential role of <sup>18</sup>F-FDG PET/CT in dermatomyositis with cardiac involvement: A case report
2023, International Journal of Rheumatic Diseases